| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | NEUTRAL | NEUTRAL | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.58▼ | 1.57▲ | 1.57▲ | 1.58▼ | 1.54▲ |
| MA10 | 1.58▲ | 1.57▲ | 1.59▼ | 1.55▲ | 1.57▲ |
| MA20 | 1.57▲ | 1.58▼ | 1.59▼ | 1.55▲ | 1.54▲ |
| MA50 | 1.57▲ | 1.58▼ | 1.56▲ | 1.59▼ | 2.26▼ |
| MA100 | 1.59▼ | 1.56▲ | 1.55▲ | 1.54▲ | 3.22▼ |
| MA200 | 1.59▼ | 1.55▲ | 1.59▼ | 1.98▼ | 4.08▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.002▼ | -0.004▼ | 0.009▲ | 0.058▲ |
| RSI | 56.788▲ | 49.646▼ | 50.614▲ | 50.767▲ | 43.495▼ |
| STOCH | 90.278▲ | 31.667 | 23.095 | 68.293 | 43.722 |
| WILL %R | -25.000▲ | -60.000 | -60.000 | -37.838 | -57.622 |
| CCI | 49.339 | 11.560 | -57.065 | 52.164 | -14.010 |
|
Wednesday, August 06, 2025 07:39 PM
MaxCyte (NASDAQ:MXCT) develops and sells cell engineering technology used primarily for cell and gene therapies. Its proprietary Flow Electroporation technology powers the ExPERT platform, which ...
|
|
Tuesday, July 22, 2025 04:30 PM
Multiple analysts have issued price targets for $MXCT recently. We have seen 2 analysts offer price targets for $MXCT in the last 6 months, with a median target of $7 ...
|
|
Monday, May 19, 2025 04:59 PM
MaxCyte Inc. Annual stock financials by MarketWatch. View the latest MXCT financial statements, income statements and financial ratios.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/12/25 | 1.56 | 1.585 | 1.56 | 1.58 | 163,919 |
| 29/12/25 | 1.60 | 1.615 | 1.575 | 1.58 | 267,105 |
| 26/12/25 | 1.60 | 1.62 | 1.56 | 1.61 | 374,565 |
| 24/12/25 | 1.54 | 1.605 | 1.54 | 1.60 | 212,313 |
| 23/12/25 | 1.60 | 1.62 | 1.52 | 1.55 | 714,214 |
| 22/12/25 | 1.51 | 1.65 | 1.50 | 1.63 | 811,850 |
| 19/12/25 | 1.51 | 1.53 | 1.48 | 1.50 | 1,668,918 |
| 18/12/25 | 1.51 | 1.54 | 1.505 | 1.52 | 484,805 |
| 17/12/25 | 1.47 | 1.53 | 1.47 | 1.49 | 651,529 |
| 16/12/25 | 1.49 | 1.54 | 1.465 | 1.47 | 653,734 |
|
|
||||
|
|
||||
|
|